Evidence map›Paper›PMID 30762077›Full record

ReviewDer Urologe. Ausg. A2019

[Do benign prostatic hyperplasia drugs affect mood or cognition?]

K F Becher, S Madersbacher, M C Michel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

K F BecherAbteilung für Geriatrie und Frührehabilitation, Helios Hanseklinikum Stralsund GmbH, Stralsund, Deutschland.
S MadersbacherAbteilung für Urologie, Kaiser Franz Josef Spital, Sigmund Freud Privatuniversität, Wien, Österreich.
M C MichelInstitut für Pharmakologie, Johannes Gutenberg Universität, Obere Zahlbacher Str. 67, 55131, Mainz, Deutschland. marmiche@uni-mainz.de.
Johannes Gutenberg University Mainz · DEKaiser-Franz-Josef-Spital · ATUniversity of Applied Sciences Stralsund · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on new evidence, we discuss the risk of central nervous side effects, mainly reduced cognition/dementia and depressive symptoms during the use of drugs for the treatment of lower urinary symptoms suggestive of benign prostatic hyperplasia. Cognitive impairments during use of muscarinic antagonists are well documented and mechanistically well understood, but their occurrence differs quantitatively between members of this drug class. The occurrence of depressive symptoms while using 5α-reductase inhibitors only became known recently but has now been observed consistently in several studies and is mechanistically plausible; it appears to occur with similar incidence when using dutasteride and finasteride. A moderate increase in new diagnoses of dementia has recently been reported from a single study upon use of tamsulosin but not other α

Indexed as

5-alpha Reductase InhibitorsAffectCognitionFinasterideProstatic HyperplasiaHumansLower Urinary Tract SymptomsMale5-alpha Reductase InhibitorsFinasteride5α-reductase inhibitorsCentral nervous systemdementiaMuscarinic receptor antagonistsSide effectsα1-adrenoceptor antagonists

Identifiers

PMID30762077
OpenAlexW2914152862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.